Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary

BACKGROUND: Melanoma of unknown primary (MUP) represents a poorly understood group of patients both clinically and immunologically. We investigated differences in prognosis and candidate immune biomarkers in patients with unknown compared with those with known primary melanoma enrolled in the E1609...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarhini, Ahmad A, Lee, Sandra J, Tan, Aik-Choon, El Naqa, Issam M, Stephen Hodi, F, Butterfield, Lisa H, LaFramboise, William A, Storkus, Walter J, Karunamurthy, Arivarasan D, Conejo-Garcia, Jose R, Hwu, Patrick, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788316/
https://www.ncbi.nlm.nih.gov/pubmed/35074904
http://dx.doi.org/10.1136/jitc-2021-004310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788316/
https://www.ncbi.nlm.nih.gov/pubmed/35074904
http://dx.doi.org/10.1136/jitc-2021-004310

Ejemplares similares